Zobrazeno 1 - 10
of 65
pro vyhledávání: '"536"'
Autor:
Carolina Reduzzi, Marta Bonotto, Alessandra Franzoni, Charles Dai, Amir Behdad, Fabio Puglisi, Roberta Mazzeo, Lorenzo Gerratana, Barbara Belletti, Andrew M. Davis, Katherine Clifton, Whitney L. Hensing, Massimo Cristofanilli, Qiang Zhang, Ami N. Shah, Marko Velimirovic, Firas Wehbe, Paolo D'Amico, Cynthia X. Ma, Aditya Bardia
Publikováno v:
Journal of Clinical Oncology. 39:1033-1033
1033 Background: The exposure to endocrine therapy (ET) can induce the onset of ESR1 gene alterations that have an impact on not only treatment resistance but also clinical phenotype. We previously demonstrated the potential of liquid biopsy in descr
Autor:
Rohit Swami, Vijay Patil, Gunjesh Kumar Singh, Nandini Menon, Vanita Noronha, Amit Joshi, Kumar Prabhash
Publikováno v:
Journal of Clinical Oncology. 38:e18525-e18525
e18525 Background: There is limited data available in the literature regarding incidence and treatment of second malignancy post-chemo-radiation (CTRT) in head and neck cancer patients. Hence we planned this analysis to address this lacuna in the cur
Publikováno v:
Journal of Clinical Oncology. 38:e24094-e24094
e24094 Background: Chemotherapy use may be associated with muscle wasting, a marker of frailty that can predispose individuals to poor outcomes. We assessed the association between pre-treatment pectoralis muscle area and overall mortality following
Autor:
Sascha A. Tuchman, William A. Wood, Ashley T. Freeman, Christopher D. Baggett, Thomas C. Shea, Anureet C. Copeland, Lei Zhou
Publikováno v:
Journal of Clinical Oncology. 35:10048-10048
10048 Background: Patients (pts) with multiple myeloma (MM) experience physical symptoms and complications from disease or treatment that include bone pain, fatigue, anorexia, and insomnia. However, the prevalence of psychiatric comorbidities and the
Publikováno v:
Journal of Clinical Oncology. 35:10112-10112
10112 Background: Pegfilgrastim is typically administered 24 hours after chemotherapy per package insert; however some pts are unable or unwilling to return for this additional visit due to work or transportation especially with regimens consisting o
Publikováno v:
Journal of Clinical Oncology. 35:268-268
268 Background: LHRH analogs are the gold standard for treatment of patients with hormone-sensitive advanced PCa. In this study, we investigated the quality of life (QoL) of PCa patients under long-term treatment with leuprorelin acetate in microcaps
Autor:
Takayuki Yoshino, Philip Clingan, György Bodoky, Kentaro Yamazaki, Shao-Chun Chang, Eric Van Cutsem, Allen Lee Cohn, Rocio Garcia-Carbonero, Pilar García-Alfonso, F. Nasroulah, Axel Grothey, Radka Obermannova, Jana Prausová, Lorinda Simms, Tae Won Kim, Tudor-Eliade Ciuleanu, Vittorina Zagonel, Josep Tabernero, David Craig Portnoy
Publikováno v:
Journal of Clinical Oncology. 33:512-512
512 Background: Angiogenesis is an important therapeutic target in CRC; VEGF plays a key role in angiogenesis. RAM is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. The RAISE study evaluated the efficacy and safety
Autor:
Daniel Egle, Christian F. Singer, Barbara Pistilli, Utpal Khambholja, José A. García-Sáenz, Maureen E. Trudeau, Feng Xu, Ron Bose, Daniel Hunt, Carlos H. Barcenas, Manuel Ruiz-Borrego, Adam Brufsky, Dieter Semsek, M. Thirlwell, K. A. Cheong, Johanna Wassermann, Naisargee Shah, Amy Jo Chien, Arlene Chan, Gavin Marx
Publikováno v:
Journal of Clinical Oncology. 39:536-536
536 Background: The primary tolerability concern with neratinib (NERLYNX®; N), an irreversible pan-HER tyrosine kinase inhibitor, is diarrhea. Data from the multi-cohort, open-label, phase 2 CONTROL trial [Barcenas et al. Ann Oncol 2020] demonstrate
Autor:
Michael W. Deininger, Jorge E. Cortes, Francisco Cervantes, Simon Purcell, Andrea Viqueira, Françoise Huguet, Eric Leip, Tim H. Brümmendorf, Dragana Milojkovic
Publikováno v:
Journal of Clinical Oncology. 39:7039-7039
7039 Background: Bosutinib (BOS) is approved for patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia (CML), at a starting dose of 400 mg QD in newly diagnosed pts in chronic phase (CP). This analysis evaluated the impact dos
Autor:
Demitrios Dedousis, Serah Choi, Jennifer E Selfridge, Ariel Ann Nelson, Petra Martin, Prateek Mendiratta, Andrew E. Sloan, David B. Mansur, Christopher J. Hoimes, Fatemeh Ardeshir-Larijani, Sree Harsha Tirumani, Nikhil H. Ramaiya, Hong De Sa
Publikováno v:
Journal of Clinical Oncology. 39:e21500-e21500
e21500 Background: Half of patients (pts) with melanoma (mel) develop central nervous system (CNS) metastases (mets), leading to death in over 90% in the pre-immune checkpoint inhibitor (ICI) era. Overall survival (OS) has improved in the ICI era for